MAPT and Alzheimer disease: The use of plasma rich in growth factors (PDGF) has been shown to induce an important decrease in brain amyloid-β (Aβ) deposition and tau phosphorylation in a mice model of AD, while also decreasing astrocyte reactivity and synaptic loss and reducing inflammatory responses, thus promoting Aβ degradation [26].